BiomX Inc. Earnings Per Share Disclosure

NOTE 17 -

BASIC LOSS PER SHARE

 

The basic and diluted net loss per share and weighted average number of shares of Common Stock used in the calculation of basic and diluted net loss per share are as follows:

 

		For the year ended December 31,
		2025				2024
Basic and diluted loss per share of common stock
Numerator:
Net loss			36,199				17,727
Denominator:
Number of shares of common stock outstanding			1,422,019				698,853
Number of shares upon Pre-Funded Warrants exercise			209,001				-
Number of shares upon fully vested Warrants exercise			17				17
Total weighted-average number of shares of common stock, shares upon Pre-Funded Warrants and fully vested Warrants exercise used in computing basic loss per share			1,631,037				698,870
Basic loss per share of common stock			22.19				25.37
Diluted net loss per share of common stock
Numerator:
Net loss			36,199				17,727
Change in fair value of Private Placement Warrants			-				26,458
Diluted net loss			36,199				44,185
Denominator:
Weighted-average number of shares of common stock outstanding			1,631,037				698,870
Private Placement Warrants			-				58,879
Total weighted-average number of shares of common stock outstanding, after giving effect to dilutive securities			1,631,037				757,749
Diluted net loss per share of common stock			22.19				58.31

 

Basic loss per share is computed on the basis of the net loss for the period divided by the weighted average number of shares of Common Stock outstanding during the period, fully vested warrants with no exercise price for the Company’s Common Stock and fully vested Pre-Funded Warrants for the Company’s Common Stock at an exercise price of $0.019 per share, as the Company considers these shares to be exercised for little to no additional consideration.

 

Diluted loss per share is based upon the weighted average number of shares of Common Stock and of potential shares of Common Stock outstanding when dilutive. Potential shares of Common Stock equivalents include outstanding stock options and warrants, which are included under the treasury stock method when dilutive.

 

The calculation of diluted loss per share as of December 31, 2025 and 2024, does not include the shares underlying the following financial instruments because their effect would be anti-dilutive:

 

		For the year ended December 31,
		2025				2024
Options			150,387				105,388
Warrants			959,687				77,647
Contingent shares			10,526				10,526
Redeemable Convertible Preferred Shares			776,383				777,553